Trial Profile
A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Cetrelimab (Primary) ; Niraparib (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms QUEST
- Sponsors Janssen Research & Development; Janssen-Cilag
- 16 Nov 2023 This study has been completed in Belgium, according to European Clinical Trials Database record.
- 15 Aug 2023 Planned End Date changed from 1 Jul 2023 to 31 Dec 2024.
- 08 May 2023 Results for efficacy and safety, published in the Oncologist